, a bio/informatics shared resource is still "open for business" - Visit the CDS website


  1. Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. Ou YC, Wen X, Johnson CA, Shae D, Ayala OD, Webb JA, Lin EC, DeLapp RC, Boyd KL, Richmond A, Mahadevan-Jansen A, Rafat M, Wilson JT, Balko JM, Tantawy MN, Vilgelm AE, Bardhan R (2020) ACS Nano 14(1): 651-663
    › Primary publication · 31851488 (PubMed)
  2. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A (2020) Clin Cancer Res
    › Primary publication · 32234759 (PubMed)
  3. Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach. Daniels AB, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, Santapuram PR, Tao YK, Boyd KL, Himmel LE, Chen SC, Du L, Friedman DL, Richmond A (2019) Invest Ophthalmol Vis Sci 60(4): 954-964
    › Primary publication · 30882851 (PubMed) · PMC6424472 (PubMed Central)
  4. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A (2019) Sci Transl Med 11(505)
    › Primary publication · 31413145 (PubMed)
  5. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Vilgelm AE, Richmond A (2019) Front Immunol : 333
    › Primary publication · 30873179 (PubMed) · PMC6400988 (PubMed Central)
  6. Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. Daniels AB, Froehler MT, Pierce JM, Nunnally AH, Calcutt MW, Bridges TM, LaNeve DC, Williams PE, Boyd KL, Reyzer ML, Lindsley CW, Friedman DL, Richmond A (2018) Invest Ophthalmol Vis Sci 59(1): 446-454
    › Primary publication · 29368001 (PubMed) · PMC5783625 (PubMed Central)
  7. Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A (2018) Cancer Immunol Res 6(10): 1186-1198
    › Primary publication · 30108045 (PubMed) · PMC6170679 (PubMed Central)
  8. Engineered microfluidic bioreactor for examining the three-dimensional breast tumor microenvironment. Rogers M, Sobolik T, Schaffer DK, Samson PC, Johnson AC, Owens P, Codreanu SG, Sherrod SD, McLean JA, Wikswo JP, Richmond A (2018) Biomicrofluidics 12(3): 034102
    › Primary publication · 29774083 (PubMed) · PMC5938175 (PubMed Central)
  9. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. Lavender N, Yang J, Chen SC, Sai J, Johnson CA, Owens P, Ayers GD, Richmond A (2017) BMC Cancer 17(1): 88
    › Primary publication · 28143493 (PubMed) · PMC5286656 (PubMed Central)
  10. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A (2017) Clin Cancer Res 23(13): 3371-3384
    › Primary publication · 28003307 (PubMed) · PMC5479746 (PubMed Central)